

09/869685




Fig 1. Docetaxel PK profile in representative patient with normal liver function (□) and patient with elevated hepatic enzymes (■—■—). Lines denote model predictions after Bayesian estimation.

09/869685

T096290 = 68969860




Fig 2. Docetaxel population PK profile in a subset of 254 patients.

09/869685

09/8696860





Fig 3. Model-predicted probability of febrile neutropenia as a function of  $CL_f$  for a patient with median AAG. Reference vertical lines denote normal  $CL$  ( $CL_f = 1$ ) and 50% reduced  $CL$  ( $CL_f = 2$ ).

## DOGETAXEL - LUNG



**Figure 4** : survival curves in NSCLC patients with low ( $\leq 1.11$  g/L, —), intermediate (1.12 to 1.84 g/L, ----) and high ( $\geq 1.85$ , -•-•-) baseline AAG (/censored observation)